---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-127657"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:37:46.104687+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants

## Summary
- 4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.
- Warrants exercisable at $4.68/share for 3 years; callable by Aileron after top-line LTI-03 Phase 1b results if VWAP exceeds exercise price.
- Net proceeds to fund LTI-03 Phase 1b trial, working capital; cash runway projected through Q2 2025.
- Offering closing on May 3, 2024; Titan Partners Group acted as sole book-runner.

## SEC filing metadata
- accession: 0001193125-24-127657
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/0001193125-24-127657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/d811393d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-127657
- JSON: https://secwatch.observer/filing/0001193125-24-127657.json
- Plain text: https://secwatch.observer/filing/0001193125-24-127657.txt

## Key facts
- Material Agreements
  Rein Therapeutics, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at combined offering price of $4.68 (effective 2024-05-01).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
  - Value: combined offering price of $4.68
  - Effective: 2024-05-01
  source text: On May 1, 2024, Aileron Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as underwriter (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 4,273,505 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants (“Warrants”) to purchase 4,273,505 shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524127657/0001193125-24-127657-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.